The cancer drug imatinib inhibits the tyrosine kinases c-Abl, c-Kit, and the PDGF receptor.
INTRODUCTION
c-Src and c-Abl are closely related tyrosine kinases that are important players in cellular signal transduction and are normally activated only in response to external signals (Hantschel and Superti-Furga, 2004; Thomas and Brugge, 1997) . c-Src was the first proto-oncogene to be identified, and the formation of a constitutively active BCR-Abl fusion protein is the underlying cause of disease in $95% of patients with chronic myelogenous leukemia (CML) (Sawyers, 2002) . Imatinib (Gleevec, Novartis), an ATPcompetitive inhibitor of the kinase domain of Abl (Figure 1A) , is highly successful in the treatment of CML (Capdeville et al., 2002; Krause and Van Etten, 2005) .
The clinical success of imatinib is due partly to the restricted specificity of the drug, which blocks BCR-Abl, c-Abl, and the receptor tyrosine kinases c-Kit and the platelet-derived growth factor receptor (PDGFR). Imatinib has much lower affinity for other kinases, including close relatives of Abl such as c-Src (Deininger et al., 2005) . The ability of imatinib to block c-Kit and PDGFR has enabled its use in the treatment of cancers that result from the activation of these receptors, such as gastrointestinal stromal tumors (GIST) (Buchdunger et al., 2000; Demetri et al., 2002) .
c-Abl resembles the Src family kinases, such as c-Src, Lck, and Hck, in that its kinase activity is inhibited by the coordinated action of SH2 and SH3 domains that are located immediately upstream of the kinase domain (Hantschel and Superti-Furga, 2004; Nagar et al., 2003) . The SH2 and SH3 domains of Src kinases dock onto the distal surface of the inactive kinase domain and are held in place by interactions between the SH2 domain and a phosphorylated tyrosine residue in the C-terminal tail (Tyr527, chicken c-Src numbering used throughout) (Schindler et al., 1999; Sicheri et al., 1997; Williams et al., 1997; Xu et al., 1997 Xu et al., , 1999 . Helix aC in the N-terminal lobe (N lobe) of the kinase domain is swung out relative to its orientation in active kinases (Knighton et al., 1991; Yamaguchi and Hendrickson, 1996) , which removes a catalytically critical glutamate side chain (Glu310) from the active site. The centrally located activation loop of the kinase domain is folded into the active site, blocking substrate access. Finally, the N-and C-terminal (C lobe) lobes of the kinase domain close over the mouth of the kinase domain.
The inactive conformations of c-Src and Hck resemble that seen originally in inactive cyclin-dependent kinase (CDK) (De Bondt et al., 1993) and more recently in other kinases, such as Abl bound to a substrate analog (Levinson et al., 2006) and the kinase domain of the epidermal growth factor (EGF) receptor (Wood et al., 2004; Zhang et al., 2006) . We refer to this closely related set of inactive conformations as the Src/CDK kinase domain conformation.
The kinase domain of c-Abl bound to imatinib is in an inactive conformation that is distinct from the Src/CDK (Nagar et al., 2003) . The Ca atoms of residues that interact with imatinib are depicted as spheres. Blue, residues that are invariant among Abl, c-Src, Lck, Hck, PDGFR, and c-Kit; yellow, residues that are identical between Abl and c-Src, but not between Abl and c-Kit or PDGFR; red, residues unique to Abl. Schindler et al., 2000) . Key differences involve helix aC, which is in an inwardly rotated conformation, and the disposition of the N and C lobes of the kinase domain, which are open. The defining feature of the imatinib-bound conformation concerns a conserved Asp-Phe-Gly motif (DFG motif), located at the N-terminal end of the activation loop; the backbone of this motif is flipped by $180 with respect to its orientation in active tyrosine kinases and in the inactive Src/CDK conformation ( Figure 2) .
The flipped DFG motif in the Ablimatinib complex has the phenylalanine side chain occupying the position normally taken by the aspartate side chain (Figure 2) Schindler et al., 2000) . This is essential for the binding of imatinib because the position of the phenylalanine side chain in the active conformation overlaps with the benzamide group of imatinib ( Figure 2 ). The unphosphorylated activation loop is folded into the active site of the kinase domain such that the central portion of the loop mimics a bound peptide substrate. Phosphorylation of Tyr393 (Abl-1a numbering) in the activation loop is expected to stabilize an open and active conformation of the activation loop that is inconsistent with DFG flipping.
The essential features of the Ablimatinib complex are also seen in a structure of the c-Kit kinase domain bound to imatinib (Mol et al., 2004) , and we refer to this DFGflipped conformation as the inactive ''Abl/c-Kit'' conformation. The Abl/c-Kit conformation is relevant for the physiological action of the drug, as demonstrated by the location of resistance mutations in BCR-Abl that arise in CML patients who are being treated with imatinib (Shah et al., 2002) . c-Src is inhibited by imatinib to a much lesser extent than Abl and c-Kit, with a reported IC 50 value of >100 mM, compared to 0.025-0.2 mM for Abl and 0.4 mM for c-Kit (Deininger et al., 2005) . Since the inactive Src/CDK conformation does not involve a flipped DFG motif, the resistance of c-Src to imatinib appears to be due to adoption of a distinctive inactive structure (Schindler et al., 2000) . But one puzzling aspect of the specificity of imatinib is that the imatinib-sensitive kinases deviate more from each other in sequence than they do from c-Src ( Figures 1B and 1C) . The human Abl kinase domain shares 35.1% and 36.6% sequence identity, respectively, with PDGFR and c-Kit. The sequence identity between Abl and the Src family kinases is $46% in the kinase domain. Every residue that makes contact with the drug in Abl is either conserved in c-Src or is replaced by a smaller residue ( Figures 1B and 1C) . Out of the 21 residues that make direct contact with imatinib in the Ablimatinib structure, 18 residues are identical in c-Src, but only 15 and 16 residues are identical in c-Kit and PDGFR, respectively ( Figures 1B and 1C) .
One of the Src kinases, Lck, does show significant sensitivity toward imatinib (Seggewiss et al., 2005) . Since Lck is closely related to c-Src and is expected to be structurally similar, one possibility is that imatinib binds to the Src kinases without requiring the DFG flip. This is suggested by the fact that imatinib binds to the Syk tyrosine kinase, a relative of the T cell receptor-associated tyrosine kinase ZAP-70, without a flipped DFG motif (Atwell et al., 2004) . Imatinib binds weakly to Syk (K D = $5 mM) and does so by adopting a more compact conformation, due to rotation around the amino group of the phenylaminopyrimidine ( Figure 1A ) (Atwell et al., 2004) . Syk has a large residue at the ''gatekeeper'' position within the active site (Met448 in Syk; Thr in Abl, c-Src, c-Kit, and PDGFR), which prevents imatinib from adopting an extended conformation. A similar compact conformation of a more flexible variant of imatinib, in which the methyl group attached to the phenyl group is removed, is seen in complex with c-Src in an active conformation (Cowan-Jacob et al., 2005) .
In this paper, we investigate the structural basis for the resistance of the c-Src kinase domain to inhibition by imatinib. We show that imatinib binds $2400 times more weakly to the c-Src kinase domain than it does to that of Abl, consistent with previous reports (Deininger et al., 2005) . This difference is not due to a difference in autophosphorylation kinetics (c-Src autophosphorylates more readily than does Abl, which might have provided an explanation for the difference in apparent affinity). By determining the structure of an imatinib complex at 2.1 Å resolution, we show that the c-Src kinase domain adopts the DFG-flipped conformation that is characteristic of inactive Abl and c-Kit, and that imatinib is bound in an extended conformation. From localized differences in protein conformation and sequence we identified sets of residues that could, in principle, increase the sensitivity of c-Src to imatinib if swapped by the corresponding residues in Abl. None of these swaps, carried out either singly or in limited combinations, resulted in a significant increase in affinity for imatinib, suggesting that the imatinib resistance of c-Src is due to a distributed set of effects.
RESULTS AND DISCUSSION
Imatinib Sensitivity of the Src Family Kinases c-Src, Hck, and Lck We expressed the kinase domains of Abl and three Src family kinases, c-Src, Hck, and Lck, in E. coli (Seeliger et al., 2005) and analyzed their sensitivity to imatinib by using an in vitro kinase-coupled assay (Barker et al., 1995) . For c-Src, we use a kinase domain construct (residues Gln251-Leu533) that contains three extra N-terminal residues (Gly-His-Met) originating from the tobacco etch virus (TEV) protease cleavage site and two sequence substitutions (T354M, E502D) relative to the sequence of the human c-Src kinase domain. These two solventexposed residues are located in the aD helix (Thr354) and in the aH-aI loop (Glu502), and neither is close to the imatinib-binding site ( Figure 7A ).
We measured enzymatic activity by using a 15-30 nM kinase, 275 mM ATP, and 500 mM of the optimal peptide substrate for Abl kinase (sequence: EAIYAAPFAKKK) (Songyang et al., 1995) . We found that the value of the inhibition constant, K i , for Abl kinase domain inhibition by imatinib is 0.013 mM, whereas the c-Src kinase domain is much less sensitive (K i = $31 mM) ( Figure 3A ). Kinase domain constructs of Lck (K i = 0.4 mM) and Hck (K i = 8.9 mM) show an intermediate affinity for imatinib ( Figure 3A ), in agreement with a previously reported K i value for Lck (0.8 mM) (Seggewiss et al., 2005) .
As noted previously, activation-loop phosphorylation is likely to destabilize the DFG-flipped conformation of the kinase domain (Schindler et al., 2000) . We found that for the Abl and Lck kinase domains the value of K i increased 140-fold and 65-fold, respectively, upon activation-loop phosphorylation ( Figure 3A ). The additional effect of activation-loop phosphorylation on c-Src could not be determined because the value of K i for unphosphorylated c-Src ($31 mM) is already at the upper end of what can be measured reliably in the enzymatic assay.
Since the enzymatic assays are carried out in the presence of ATP, we investigated whether the resistance of c-Src to imatinib is due to rapid autophosphorylation. We compared the rates of autophosphorylation of the Abl and c-Src kinase domains at 1 mM and 30 nM protein concentrations ( Figure 4 ). While the c-Src kinase domain shows detectable levels of phosphorylation within 2 min at a 1 mM protein concentration, there is no detectable phosphorylation when the protein concentration is reduced to 30 nM. Detection relied on an anti-phosphotyrosine-specific antibody, and it is possible that the observed phosphorylation is not on the activation-loop tyrosine. Nevertheless, the critical point is that c-Src does not autophosphorylate significantly under the conditions of the enzyme assay (30 nM kinase concentration). The Abl kinase domain does not autophosphorylate noticeably at either 1 mM or 30 nM concentrations.
Measurement of Binding Affinity by Calorimetry
We determined the dissociation constants, K D , of imatinib binding to the Abl and c-Src kinase domains by isothermal titration calorimetry (ITC), obtaining values of $0.08 mM and >10 mM, respectively (Figures 5A and 5C). Data were fit to a binding model that assumes one set of identical binding sites, which yields a stoichiometry of 0.97 molecules of imatinib per molecule of c-Abl and 0.84 molecules of imatinib per molecule of c-Src. Due to the solubility limit of the drug, a more precise measurement was not possible for c-Src ( Figures 5B and 5D ). These measurements were carried out by using unphosphorylated kinase domain, as documented by mass spectrometry (data not shown), further confirming that the affinity of c-Src for imatinib is intrinsically low. Activation-loop phosphorylation significantly reduces the affinity of imatinib for the Abl kinase domain, with K D = 1.6 mM for the Abl kinase domain that is phosphorylated on the activation loop ( Figure 5C ). These values are comparable to the values of K i obtained for the unphosphorylated and phosphorylated forms of the Abl kinase domain (0.013 mM and 1.84 mM, respectively).
The Association Rate of Imatinib Is Much Lower for c-Src than for Abl
We monitored the rate of imatinib binding to c-Abl and c-Src by measuring the decrease in protein fluorescence upon drug binding. Under conditions of pseudo first-order kinetics (at least 10-fold excess of imatinib over protein), this assay allows us to determine the rate constant for drug binding (k on ) and, by extrapolation, to estimate the dissociation rate constant (k off ) of the protein-drug complex ( Figure 6 ) (Fersht, 1999) .
Imatinib binds to Abl $50 times faster than it does to c-Src (k on = 0.146 mM The surface of imatinib bound to Abl (PDB code 1OPJ [Nagar et al., 2003] ) is shown and is superposed upon inactive c-Src in the Src/CDK conformation (PDB code 2SRC [Xu et al., 1999] ), active Lck (PDB code 3LCK [Yamaguchi and Hendrickson, 1996] ), the c-Src structure in the imatinib complex (this work, PDB code 2OIQ), and the Ablimatinib complex (PDB code 1OPJ). For the c-Srcimatinib complex, electron density for imatinib is shown calculated before imatinib was included in the refinement and contoured at 3s. Protein structures were aligned on the Ca atoms of the displayed Abl fragment (Abl residues 380-403, PDB code 1OPJ). . The reliability with which k off can be determined is limited due to the extrapolation of the observed pseudo first-order rate constant (k o ) to zero drug concentration. A small error in the estimation of the slope will yield a large error in k off relative to k on (Table 1) . The values of k off and K D can only be determined accurately for slow-binding systems like c-Src. Neverthelesss, the dramatic difference in the on rates, which are determined reliably, underscores the impeded binding of imatinib to the c-Src kinase domain.
Crystal Structure of the c-SrcImatinib Complex
We cocrystallized imatinib with the c-Src kinase domain and determined the structure of the complex at 2.1 Å resolution by molecular replacement (Table 1 ). The unit cell is nearly monoclinic (Table 1) , but the data cannot be processed by using P2 symmetry. We found no evidence for a significant degree of pseudo-merohedral twinning. The crystals have two molecules of c-Src in the asymmetric unit, referred to as A and B. There is well-defined electron density for imatinib in molecule A (Figure 2 ), which appears to be bound with full occupancy. The average temperature factor for the drug is 34.4 Å 2 , compared to 40.5 Å 2 for all protein atoms in molecule A. Imatinib does not appear to be bound to molecule B, which is in an active conformation that is very similar to the structure of the kinase domain of a Src-inhibitor complex described previously (Cowan-Jacob et al., 2005) , and we do not discuss it further.
Imatinib binds to c-Src in the extended ''trans'' conformation seen in the c-Ablimatinib and c-Kitimatinib complexes (Mol et al., 2004; Nagar et al., 2002; Schindler et al., 2000) . The structure of the imatinib-binding pocket is very similar in the c-Src, c-Abl, and c-Kit complexes with imatinib ( Figure S3 ; see the Supplemental Data available with this article online).
Only two regions in the c-Srcimatinib complex deviate significantly from the structure of Ablimatinib: the phosphate-binding loop (P loop) (c-Src residues 273-282) and the activation loop (c-Src residues 404-425), the central portion of which is disordered (c-Src residues 408-420) (Figure 7) . When compared to the Src/CDK inactive conformation, helix aC in the c-Srcimatinib complex is rotated inward, and the DFG motif is flipped. There is also a small but significant change in the global conformation of the kinase domain. In order to accommodate the drug, the kinase domain of c-Src opens up with respect to the inactive Src/CDK conformation. This is illustrated in Figure 8A , which shows a Ca-Ca difference distance matrix that compares the c-Srcimatinib complex to c-Src in the Src/CDK inactive form. A similar matrix for the comparison of c-Srcimatinib to Ablimatinib is (C) The pseudo first-order rate constants were plotted against the imatinib concentration and were fit to a linear equation (Fersht, 1999) . The slope of the fitted line yields the association rate constant, k on , and the intercept yields the dissociation rate constant, k off .
(D) Comparison of association rate constants for c-Src and c-Abl kinase domain constructs. The dissociation constants calculated from the on and off rates together with the errors are shown in Table S1 . Error bars indicate the uncertainties of the least mean square fit to the experimental data in the k o versus imatinib plot. Figure 8B) . One difference between the imatinib complexes of c-Src and Abl concerns the location of the side chain of an arginine residue (Arg388 in c-Src) that is replaced by alanine in Abl and c-Kit. Reciprocally, Ala390 in c-Src is replaced by Arg365 in Abl and Arg796 in c-Kit, and the guanidinium groups of the three arginines are overlapped spatially. This corresponds to the replacement of a 388 ArgAla-Ala 390 motif in the Src kinases by an Ala-Ala-Arg motif in Abl and c-Kit. This alteration is potentially significant because, although the arginine side chains are in equivalent positions from the point of view of the catalytic mechanism, the direction of Arg388 in c-Src is such that the activation-loop tyrosine (Tyr416) would clash with the guanidinium group of Arg388 if the central portion of the activation loop were to adopt the conformation observed in Ablimatinib. This clash might explain the observed disorder of residues 408-420 in the c-Src activation loop in the imatinib complex.
The P loop in the imatinib-bound structure of Abl is kinked toward the C lobe of the kinase domain, and it provides a water-excluding enclosure for the drug (Schindler et al., 2000) . This conformation enables the formation of hydrogen bonds between Tyr253 and Gln252 in the P loop with the backbone and side chain of Asn322 ( Figure 7B ). Tyr253 also interacts with Phe405 in the DFG motif in a perpendicular aromatic-aromatic interaction. These two interactions are absent in c-Src, in which the P loop is in an extended conformation.
The significance of the altered P loop conformation in c-Src is unclear, because the P loop in the c-Kitimatinib complex is also in an extended conformation (Mol et al., 2004) (Figure 7C ). The P loop orientation in c-Kit is stabilized by a single helical turn in the activation loop, immediately after the DFG motif. A corresponding helical turn is present in both the active and the inactive Src/Cdk conformations of Src kinases (Schindler et al., 1999; Xu et al., 1999; Yamaguchi and Hendrickson, 1996) , but whether it plays a role in the recognition of imatinib is unclear because the activation loop is disordered after the DFG motif in the c-Srcimatinib complex.
The c-Src Scaffold Is Resistant to Imatinib Binding
There are a total of 150 sequence differences between the kinase domains of Abl and c-Src (Figure 1 ). We used these differences to explore whether it is possible to increase the sensitivity of c-Src to imatinib by a limited set of mutations. We focused on sequence changes in regions immediately adjacent to the drug-binding site that are structurally different in the c-Srcimatinib and the Ablimatinib complexes.
A list of the tested mutations and the corresponding values of K i for imatinib inhibition are shown in Figure 3B . The specific activities of all of the mutant proteins, except for one (F405A, in the DFG motif), were within a factor of 10 of the wild-type-specific activity (a representative set of kinetic data is shown in Figure S1 ), indicating that these mutations (except for F405A) do not adversely affect the structural stability of the protein. Given the central location of Phe405 within the catalytic core of the enzyme, the $50-fold reduction in specific activity for the F405A mutation is not surprising ( Figure S1 ).
The P loop is an important site of patient resistance mutations in BCR-Abl (Shah et al., 2002) . For example, E255K, Y253F, and Q252 H/R are mutations that are frequently found in BCR-Abl (Abl-1a numbering). Of these, Glu255 is conserved in c-Src, but Tyr253 and Gln252 in Abl are replaced by Phe278 and Cys277, respectively, in c-Src. Additionally, Gly250 in the Abl P loop is replaced by Gln275 in c-Src. We replaced P loop residues in c-Src with the corresponding residues in Abl either individually (Q275G, F278Y; see entries 8 and 9 in Figure 3B ) or as part of larger combinations of mutations (C277Q; see entries 12 and 17 in Figure 3B ). These mutations did not significantly increase the sensitivity of c-Src to imatinib.
As noted previously, the replacement of the 388 Arg-Ala- Numbers in parentheses refer to the outer resolution shell (2.07 Å -2.14 Å ).
multiple hydrogen bonds with the arginine side chain as well as with other residues. We therefore replaced the c-Src motif with that found in Abl (R388A, A390R), either as a single pair of mutations (entry 13; Figure 3B ) or in combination with other mutations, including activationloop swaps (entries 14-17; Figure 3B ). No significant improvement in binding affinity was obtained.
The activation loops of c-Src (Asp404 to Pro425) and Abl (Asp381 to Pro402) are the same length, but they contain eight substitutions in three blocks (Figure 1 ). The first block contains a single substitution, with Ser385 in Abl replaced by Ala408 in c-Src. Ser385 is in a solventexposed position in the Ablimatinib complex, and it makes no interactions with other residues. The corresponding residue in both c-Kit and PDGFR is alanine; thus, we did not investigate this residue further.
The second block involves the segment 388 MTGDT 392 in Abl, which is replaced in c-Src by 411 IEDNE 415 . We swapped this motif in c-Src with the corresponding Abl sequence, in isolation or in combination with other mutations (entries 3-7, 11-12, and 14-17, Figure 3B ), without increasing imatinib sensitivity.
The third block involves two residues, 396 HA 397 , which are replaced by 419 
RQ
420 in c-Src. Ala397 in Abl and the corresponding Gln420 in c-Src are both surface exposed and highly variable in the kinases under consideration ( Figure 1C ), and we did not consider them further. His396 in BCR-Abl is replaced by either proline or arginine in imatinib-resistance mutations (Shah et al., 2002) , which causes resistance because the allowed backbone torsion angles of proline cannot be accommodated within the inactive Abl/c-Kit conformation . The replacement of His396 in Abl by Arg419 in c-Src is interesting, because this residue plays a role in stabilizing the activation loop in the inactive Src/CDK conformation ( Figure S2 ). The R419H and R419A variants of c-Src, although still not very sensitive to imatinib, have somewhat reduced K i values of 9.1 mM and 20.5 mM, respectively, compared to $31 mM for wild-type c-Src (entries 1 and 2, Figure 3B ). These mutations may destabilize the inactive Src/CDK conformation, a point we return to in the next section. In addition, since His396 makes a hydrogen bond with the protein backbone in the inactive Abl/c-Kit conformation, the R419H mutation in c-Src might be Increase in Imatinib Affinity upon Destabilization of the Inactive Src/CDK Conformation As has been noted previously in an analysis of the EGF receptor kinase domain, hydrophobic side chains located in the activation loop immediately after the DFG motif are likely to stabilize the inactive Src/CDK conformation (Zhang et al., 2006) . We found that mutation of one such residue in c-Src, Leu407, to glycine increases c-Src affinity for imatinib by $8-fold ( Figure 3B ). The corresponding mutation in Abl (L384G) had no effect on imatinib binding ( Figure 5 ). Another residue that is likely to stabilize the inactive Src/CDK conformation is Trp260 in c-Src and Hck (LaFevre-Bernt et al., 1998) . Combination of the L407G mutation with the W260A mutation further increases the affinity of c-Src for imatinib to a K i value of 2.0 mM, resulting in 15-fold higher affinity for imatinib with respect to the wild-type kinase domain ( Figure 3B ). Not all mutations that might be expected to destabilize the inactive Src/CDK conformation resulted in a consistent increase in imatinib sensitivity. There are interactions between the loop connecting strand b3 to helix aC in the inactive Src/c-Kit conformation (Gonfloni et al., 2000) that are absent in the inactive Abl/c-Kit conformation. We replaced two proline residues in the loop in c-Src with glutamates (P299E, P304E; entries 12, 17, and 22, Figure 3B ). When introduced as an individual pair of mutations, these replacements reduced the value of K i slightly, to 21.1 mM (entry 22), but this reduction is not apparent when the two mutations are combined with others (entries 12 and 17).
Conclusions
In this paper, we present a crystal structure of imatinib bound to the kinase domain of c-Src. Although imatinib does not bind to c-Src with high affinity, the crystal structure shows that the Src kinase domain is capable of adopting the DFG-flipped inactive conformation that is characteristic of the Abl and c-Kit complexes with imatinib. Since residues that make contact with the drug are highly conserved in c-Src, the crystal structure of the imatinib complex makes the low affinity of c-Src for imatinib all the more puzzling. This situation contrasts with that for other kinases, for which simple sequence-based explanations are sufficient to understand imatinib resistance. For example both Flt3 and Syk have bulky residues at the gatekeeper position in the active site, and imatinib cannot be accommodated in the extended conformation that is presumably required for high affinity.
The in vivo specificity of imatinib depends on a number of factors, including the interplay of kinases with phosphatases and the allosteric effects of regulatory domains that are not included in our study. Nevertheless, our results make clear that the unphosphorylated kinase domain of Src is intrinsically resistant to imatinib, which binds $2400 times less tightly to it than the Abl kinase domain, corresponding to a $4.6 kcal/mole penalty in terms of relative binding energy.
Our attempts to engineer imatinib sensitivity into the c-Src kinase domain have been unsuccessful so far. We selected residues in c-Src that are the most obvious candidates for imposing restrictions on imatinib binding and replaced them with the corresponding residues in Abl. These include residues in the P loop and the activation loop, which are structurally different in the Srcimatinib complex when compared to the Abl complex. None of the residue swaps resulted in an increased affinity for imatinib. These results suggest that the free-energy penalty for imatinib binding to c-Src arises from a distributed set of factors. It would be informative to carry out a saturation mutagenesis screen to see if residues located far from the imatinib-binding site could affect affinity through allosteric mechanisms, as is the case with certain BCR-Abl-resistance mutations (Azam et al., 2003) .
The only mutations for which we see a detectable improvement in binding affinity are those that were designed to destabilize the inactive Src/CDK conformation of c-Src. We have previously shown that the Abl kinase domain can adopt an inactive Src/CDK conformation, and we had speculated that one set of imatinib-resistant mutations in BCR-Abl might function by stabilizing the inactive Src/CDK conformation relative to the inactive Abl/c-Kit (Levinson et al., 2006) . In the present work, we show that Src can adopt the inactive Abl/c-Kit conformation, but that the conformational balance is tuned differently than in Abl (Figure 9 ). Understanding the molecular principles that govern this free-energy balance will be an important aspect of gaining a more complete understanding of kinase inhibitor specificity.
EXPERIMENTAL PROCEDURES

Protein Expression and Purification
Kinase domain constructs (human c-Abl, residues 229-512; chicken c-Src, residues 251-533; murine Lck, residues 227-509; human Hck, residues 166-445) were expressed as described previously for Abl and c-Src (Seeliger et al., 2005) . Genes encoding the constructs were cloned into pET28, modified to yield an N-terminal, TEV-cleavable His tag. Proteins were coexpressed with YopH phosphatase (Bliska et al., 1991) and purified by immobilized metal ion affinity chromatography, anion exchange chromatography, and size-exclusion chromatography. Proteins in 20 mM Tris (pH 8.0), 100 mM NaCl, 5% glycerol, 1 mM DTT were concentrated, frozen in liquid nitrogen, and stored at À80 C.
Yields of purified protein per liter of culture ranged from 15 mg (c-Src kinase domain) to 0.15 mg (Lck constructs). Mutations were generated with the QuikChange kit (Stratagene) and were confirmed by DNA sequencing and mass spectrometry (D. King, HHMI, UC Berkeley). Activation-loop-phosphorylated Abl kinase domain was prepared through phosphorylation with affinity-tagged Hck kinase and ion exchange chromatography.
Crystallization and Structure Determination
The c-Srcimatinib complex was formed in a solution of 330 mM kinase domain, 500 mM imatinib, 5% DMSO, 20 mM Tris (pH 8.0), 100 mM NaCl, 1 mM DTT. Using the hanging drop vapor diffusion method (1 ml protein + 1 ml mother liquor), crystals grew overnight at 20 C in a mother liquor of 0.1 M MES (pH 6.5), 4% glycerol, 12% PEG 4000, 50 mM sodium acetate. Crystals were cryoprotected in mother liquor plus 20% glycerol, frozen, and stored in liquid nitrogen. Diffraction data were collected at the Advanced Light Source (Lawrence Berkeley National Laboratory) beamline 8.2.1. Data were processed in space group P1 (Table 1) by using DENZO and Scalepack (Otwinowski and Minor, 1997) . The structure was solved by molecular replacement by using the kinase domain of human c-Src (PDB code 2SRC) (Xu et al., 1999) (residues 260-520) without the C helix (residues 298-310) and the activation loop (residues 400-425) as the template in Phaser (McCoy et al., 2005 ) of ccp4i. The structure was built in O (Jones et al., 1991) and Coot (Emsley and Cowtan, 2004 ), and refinement of the structure was straightforward and was conducted by using CNS (Brunger et al., 1998) .
Kinase Assays and Imatinib Inhibition
Kinase assays with a substrate peptide (Songyang et al., 1995) (sequence: EAIYAAPFAKKK) relied on a continuous spectrophotometric assay (Barker et al., 1995) , and imatinib titrations were performed as described (Seeliger et al., 2005) . Inhibitory constants (K i ) were calculated from the imatinib concentration that causes 50% inhibition (IC 50 ) according to the following relationship (Cheng and Prusoff, 1973) :
where [ATP] is the concentration of ATP in the assay (typically 275 mM) and K M is the Michaelis constant for ATP, which was determined for the Src and Abl wild-type kinase domains to be 70 mM; this value was used for all mutant proteins.
Measurement of Imatinib Binding
Isothermal titration calorimetry was carried out as described (Seeliger et al., 2005) . For the fluorescence kinetics measurements, equal volumes of protein at 100 nM concentration in 50 mM Tris (pH 8.0), 100 mM NaCl, 5% glycerol, 1 mM DTT, and imatinib at concentrations ranging from 1 mM to 200 mM in identical buffer were mixed at room temperature in a rapid-mixing instrument (Applied Photophysics, Leatherhead, UK). The decrease of protein fluorescence at 350 nm upon excitation at 290 nm was monitored on a HORIBA Jobin Yvon FluoroMax-3 (Edison, NJ) spectrofluorimeter. Each transient was measured over 10-20 half-lives with 1000-2000 time points and at least 3 repeats per experiments. Data were fit to a single exponential with a sloping baseline to account for photobleaching. The observed rate constant was plotted against the final imatinib concentration and was fit to a linear function where the slope yields the binding rate constant and the intercept yields the dissociation rate constant (Fersht, 1999) .
Supplemental Data
Supplemental Data include samples of enzymatic inhibition curves ( Figure S1 ), an illustration of residue Arg419 stabilizing the Src inactive conformation ( Figure S2 ), and a comparison of the imatinib-binding pocket in c-Src and c-Kit ( Figure S3 ) and are available at http:// www.structure.org/cgi/content/full/15/3/299/DC1/. 
